What Awaits These 4 Biotech Stocks That More Than Doubled in 2024
Insider Sale: See Remarks of $ARQT (ARQT) Sells 15,000 Shares
Arcutis Biotherapeutics Soars on Zoryve Success and Bullish Analyst Ratings
Arcutis Submits ZORYVE (Roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 With Mild to Moderate Atopic Dermatitis
Express News | Arcutis Submits Zoryve® (Roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 With Mild to Moderate Atopic Dermatitis
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and Warby Parker (WRBY)
